# Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

> **NCT01180049** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 101 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** temsirolimus
- **DRUG:** temsirolimus

## Key facts

- **NCT ID:** NCT01180049
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2015-11
- **Final completion:** 2018-06
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01180049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01180049, "Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01180049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*